UiPath Stock Gains 33% in 6 Months: Should You Buy, Hold or Fold?

UiPath shares gained 33% over six months, while fiscal Q2 2027 revenue rose 13% year over year to $410 million and ARR increased 12% to $1.94 billion. Non-GAAP operating income was $89 million, a 22% margin, and the company posted its fourth consecutive GAAP-profitable quarter; it had about $1.4 billion in cash and no debt. Fiscal 2028 EPS is forecast to rise 14.1% to $0.91, and its forward P/E of 15.29 is below the industry’s 30.92. The article recommends buying, while noting competition and uncertain enterprise spending as risks.

Analysis

UiPath’s key investment question is not whether enterprises are experimenting with AI automation, but whether Maestro turns that interest into durable, paid workflow orchestration. AI-related large deals are evidence of sales engagement—not, by themselves, proof of incremental contract value, renewal durability, or pricing power. Agentic tools could expand UiPath’s addressable workflows, but they could also commoditize task automation as Microsoft and other platform vendors bundle agents into software customers already buy. That is the central risk to both growth and the valuation discount thesis.

The article’s low forward P/E is not a sufficient margin of safety: validate the earnings basis and compare it with recurring-revenue growth, cash conversion, and dilution before treating the industry multiple gap as upside. Cognizant (CTSH) could benefit if deployments require substantial integration work, though services-led implementation may capture value that investors otherwise attribute to UiPath. ServiceNow (NOW) is a stronger platform competitor; Pegasystems (PEGA) is another workflow alternative, but the supplied evidence does not support a relative-value short.

Near term, the six-month rally raises the bar for execution. Over the next 1–3 months, watch guidance, ARR growth, retention/expansion, and whether AI deals convert into larger recurring commitments. Over 6–18 months, sustained acceleration and operating leverage would support the bull case; bundled competition, slower enterprise budgets, or weaker renewals would undermine it. Contrarian view: the discount may reflect genuine uncertainty about monetization and displacement, not overlooked value.

Key Decisions for Investors

• Do not chase the rally on the P/E comparison alone. For investors seeking exposure, consider a staged PATH entry after results confirm recurring-revenue conversion and retention; no price target is warranted from the supplied data.
• Existing holders can maintain a measured position, but reassess if guidance or ARR growth weakens, renewals deteriorate, or AI adoption fails to translate into recurring contract expansion.
• Treat CTSH as a potential implementation beneficiary, not a direct proxy for UiPath’s software economics; monitor evidence that deployment activity is producing material services demand before trading the spillover.
• Avoid a PATH-versus-NOW or PATH-versus-PEGA pair on this evidence: product overlap is clear, but comparative valuation, growth, and customer-win data are missing.